Baidu
map

J Clin Endocrinol Metab:上海巴斯德所等揭示炎性因子IL-17A调控甲状腺相关眼病发生发展新机制

2017-04-27 佚名 上海巴斯德研究

近期,美国内分泌学会主办的学术期刊Journal of Clinical Endocrinology and Metabolism 在线发表了中国科学院上海巴斯德研究所李斌课题组与中国科学院上海生命科学研究院/上海交通大学医学院健康科学研究所范先群课题组的合作研究成果,揭示了炎性因子IL-17A调控甲状腺相关眼病(Thyroid-associated ophthalmopathy,TAO)发生发展

近期,美国内分泌学会主办的学术期刊Journal of Clinical Endocrinology and Metabolism 在线发表了中国科学院上海巴斯德研究所李斌课题组与中国科学院上海生命科学研究院/上海交通大学医学院健康科学研究所范先群课题组的合作研究成果,揭示了炎性因子IL-17A调控甲状腺相关眼病(Thyroid-associated ophthalmopathy,TAO)发生发展的新机制。

TAO是累及眼眶及其周围组织的自身免疫性疾病,其发病率逐年上升,在成人眼眶病中居首位。该疾病临床表现为淋巴细胞过度浸润、脂肪异常增生和眼外肌纤维化变性,引起眼球突出、眼睑退缩、眼球运动障碍、斜视、复视,压迫性视神经病变、暴露性角膜炎,视力下降甚至失明等症状,严重危害患者的视功能和颅面外形,给家庭和社会造成沉重的负担。

上海交通大学医学院附属第九人民医院眼科博士研究生方思捷、硕士研究生黄雅琢,上海巴斯德所分子免疫学课题组、上海大学联合培养硕士研究生王帅威等在李斌、范先群、周慧芳的合作指导下,通过分析TAO患者外周血免疫细胞表型,发现患者体内增高的IL-17A来源于Th17细胞、Tc17细胞和部分γδ T细胞。在TAO患者眼眶组织内,IL-17A,IL-6,IL-23,IL-1β和TGF-β等炎性因子水平远远高于健康人群。进一步研究发现,IL-17A与TAO 患者眼眶成纤维细胞高表达的IL-17RA受体结合后,可以通过激活下游丝裂原活化蛋白激酶(MAPK)信号转导途径(包括ERK1/2、p38和JNK途径),促进眼眶成纤维细胞分泌炎症因子和趋化因子,同时促进细胞外基质大量合成,导致TAO自身免疫性病变及纤维化病理变性。结合课题组前期成果,研究人员利用来自树菇类莲座革菌的天然单分子产物组分Vialinin A,抑制RORγt的去泛素化酶USP4活性来下调细胞内RORγt蛋白水平,从而抑制TAO患者体外培养炎性Th17及Tc17细胞功能。该研究对控制炎症环境下Th17细胞炎性细胞因子IL-17A的过度产生具有重要的指导性意义及潜在临床应用价值,为TAO及相关自身免疫性疾病临床诊治提供了新靶点和理论基础。

该项研究获得科技部“973”项目、国家杰出青年基金、国家自然科学基金委面上及重点项目等经费支持。

原始出处:

Sijie Fang, Yazhuo Huang, Shuaiwei Wang, et al.IL-17A Exacerbates Fibrosis by Promoting the Proinflammatory and Profibrotic Function of Orbital Fibroblasts in TAO.J Clin Endocrinol Metab. 2016 Aug

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (7)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1896030, encodeId=5dcd189603060, content=<a href='/topic/show?id=4a391158248' target=_blank style='color:#2F92EE;'>#MET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11582, encryptionId=4a391158248, topicName=MET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18fc139, createdName=一闲, createdTime=Thu Feb 22 04:58:00 CST 2018, time=2018-02-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1887618, encodeId=2fa3188e61817, content=<a href='/topic/show?id=d56611584ec' target=_blank style='color:#2F92EE;'>#Meta#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11584, encryptionId=d56611584ec, topicName=Meta)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d8f4110, createdName=guojianrong, createdTime=Mon May 15 13:58:00 CST 2017, time=2017-05-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2030725, encodeId=83a02030e2530, content=<a href='/topic/show?id=71353e8964f' target=_blank style='color:#2F92EE;'>#发生发展#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37896, encryptionId=71353e8964f, topicName=发生发展)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=346311, createdName=wgsun, createdTime=Tue Jan 30 19:58:00 CST 2018, time=2018-01-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1374409, encodeId=1e7113e440987, content=<a href='/topic/show?id=1727963861' target=_blank style='color:#2F92EE;'>#IL-17#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9638, encryptionId=1727963861, topicName=IL-17)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bcaa382, createdName=fzwish20000, createdTime=Sat Apr 29 09:58:00 CST 2017, time=2017-04-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1482900, encodeId=a69f1482900ed, content=<a href='/topic/show?id=2443963952' target=_blank style='color:#2F92EE;'>#IL-17A#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=134, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9639, encryptionId=2443963952, topicName=IL-17A)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0ae57859469, createdName=12498bf3m27暂无昵称, createdTime=Sat Apr 29 09:58:00 CST 2017, time=2017-04-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1508182, encodeId=6ffb15081829f, content=<a href='/topic/show?id=8d4596248e' target=_blank style='color:#2F92EE;'>#IL-1#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9624, encryptionId=8d4596248e, topicName=IL-1)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f6cf9946833, createdName=jjjiang0202, createdTime=Sat Apr 29 09:58:00 CST 2017, time=2017-04-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1540492, encodeId=394f154049261, content=<a href='/topic/show?id=fbbce2786cc' target=_blank style='color:#2F92EE;'>#眼病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72786, encryptionId=fbbce2786cc, topicName=眼病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b85c13256921, createdName=pps20023, createdTime=Sat Apr 29 09:58:00 CST 2017, time=2017-04-29, status=1, ipAttribution=)]
    2018-02-22 一闲
  2. [GetPortalCommentsPageByObjectIdResponse(id=1896030, encodeId=5dcd189603060, content=<a href='/topic/show?id=4a391158248' target=_blank style='color:#2F92EE;'>#MET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11582, encryptionId=4a391158248, topicName=MET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18fc139, createdName=一闲, createdTime=Thu Feb 22 04:58:00 CST 2018, time=2018-02-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1887618, encodeId=2fa3188e61817, content=<a href='/topic/show?id=d56611584ec' target=_blank style='color:#2F92EE;'>#Meta#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11584, encryptionId=d56611584ec, topicName=Meta)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d8f4110, createdName=guojianrong, createdTime=Mon May 15 13:58:00 CST 2017, time=2017-05-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2030725, encodeId=83a02030e2530, content=<a href='/topic/show?id=71353e8964f' target=_blank style='color:#2F92EE;'>#发生发展#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37896, encryptionId=71353e8964f, topicName=发生发展)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=346311, createdName=wgsun, createdTime=Tue Jan 30 19:58:00 CST 2018, time=2018-01-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1374409, encodeId=1e7113e440987, content=<a href='/topic/show?id=1727963861' target=_blank style='color:#2F92EE;'>#IL-17#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9638, encryptionId=1727963861, topicName=IL-17)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bcaa382, createdName=fzwish20000, createdTime=Sat Apr 29 09:58:00 CST 2017, time=2017-04-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1482900, encodeId=a69f1482900ed, content=<a href='/topic/show?id=2443963952' target=_blank style='color:#2F92EE;'>#IL-17A#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=134, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9639, encryptionId=2443963952, topicName=IL-17A)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0ae57859469, createdName=12498bf3m27暂无昵称, createdTime=Sat Apr 29 09:58:00 CST 2017, time=2017-04-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1508182, encodeId=6ffb15081829f, content=<a href='/topic/show?id=8d4596248e' target=_blank style='color:#2F92EE;'>#IL-1#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9624, encryptionId=8d4596248e, topicName=IL-1)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f6cf9946833, createdName=jjjiang0202, createdTime=Sat Apr 29 09:58:00 CST 2017, time=2017-04-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1540492, encodeId=394f154049261, content=<a href='/topic/show?id=fbbce2786cc' target=_blank style='color:#2F92EE;'>#眼病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72786, encryptionId=fbbce2786cc, topicName=眼病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b85c13256921, createdName=pps20023, createdTime=Sat Apr 29 09:58:00 CST 2017, time=2017-04-29, status=1, ipAttribution=)]
    2017-05-15 guojianrong
  3. [GetPortalCommentsPageByObjectIdResponse(id=1896030, encodeId=5dcd189603060, content=<a href='/topic/show?id=4a391158248' target=_blank style='color:#2F92EE;'>#MET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11582, encryptionId=4a391158248, topicName=MET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18fc139, createdName=一闲, createdTime=Thu Feb 22 04:58:00 CST 2018, time=2018-02-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1887618, encodeId=2fa3188e61817, content=<a href='/topic/show?id=d56611584ec' target=_blank style='color:#2F92EE;'>#Meta#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11584, encryptionId=d56611584ec, topicName=Meta)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d8f4110, createdName=guojianrong, createdTime=Mon May 15 13:58:00 CST 2017, time=2017-05-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2030725, encodeId=83a02030e2530, content=<a href='/topic/show?id=71353e8964f' target=_blank style='color:#2F92EE;'>#发生发展#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37896, encryptionId=71353e8964f, topicName=发生发展)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=346311, createdName=wgsun, createdTime=Tue Jan 30 19:58:00 CST 2018, time=2018-01-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1374409, encodeId=1e7113e440987, content=<a href='/topic/show?id=1727963861' target=_blank style='color:#2F92EE;'>#IL-17#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9638, encryptionId=1727963861, topicName=IL-17)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bcaa382, createdName=fzwish20000, createdTime=Sat Apr 29 09:58:00 CST 2017, time=2017-04-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1482900, encodeId=a69f1482900ed, content=<a href='/topic/show?id=2443963952' target=_blank style='color:#2F92EE;'>#IL-17A#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=134, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9639, encryptionId=2443963952, topicName=IL-17A)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0ae57859469, createdName=12498bf3m27暂无昵称, createdTime=Sat Apr 29 09:58:00 CST 2017, time=2017-04-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1508182, encodeId=6ffb15081829f, content=<a href='/topic/show?id=8d4596248e' target=_blank style='color:#2F92EE;'>#IL-1#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9624, encryptionId=8d4596248e, topicName=IL-1)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f6cf9946833, createdName=jjjiang0202, createdTime=Sat Apr 29 09:58:00 CST 2017, time=2017-04-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1540492, encodeId=394f154049261, content=<a href='/topic/show?id=fbbce2786cc' target=_blank style='color:#2F92EE;'>#眼病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72786, encryptionId=fbbce2786cc, topicName=眼病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b85c13256921, createdName=pps20023, createdTime=Sat Apr 29 09:58:00 CST 2017, time=2017-04-29, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1896030, encodeId=5dcd189603060, content=<a href='/topic/show?id=4a391158248' target=_blank style='color:#2F92EE;'>#MET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11582, encryptionId=4a391158248, topicName=MET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18fc139, createdName=一闲, createdTime=Thu Feb 22 04:58:00 CST 2018, time=2018-02-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1887618, encodeId=2fa3188e61817, content=<a href='/topic/show?id=d56611584ec' target=_blank style='color:#2F92EE;'>#Meta#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11584, encryptionId=d56611584ec, topicName=Meta)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d8f4110, createdName=guojianrong, createdTime=Mon May 15 13:58:00 CST 2017, time=2017-05-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2030725, encodeId=83a02030e2530, content=<a href='/topic/show?id=71353e8964f' target=_blank style='color:#2F92EE;'>#发生发展#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37896, encryptionId=71353e8964f, topicName=发生发展)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=346311, createdName=wgsun, createdTime=Tue Jan 30 19:58:00 CST 2018, time=2018-01-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1374409, encodeId=1e7113e440987, content=<a href='/topic/show?id=1727963861' target=_blank style='color:#2F92EE;'>#IL-17#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9638, encryptionId=1727963861, topicName=IL-17)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bcaa382, createdName=fzwish20000, createdTime=Sat Apr 29 09:58:00 CST 2017, time=2017-04-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1482900, encodeId=a69f1482900ed, content=<a href='/topic/show?id=2443963952' target=_blank style='color:#2F92EE;'>#IL-17A#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=134, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9639, encryptionId=2443963952, topicName=IL-17A)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0ae57859469, createdName=12498bf3m27暂无昵称, createdTime=Sat Apr 29 09:58:00 CST 2017, time=2017-04-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1508182, encodeId=6ffb15081829f, content=<a href='/topic/show?id=8d4596248e' target=_blank style='color:#2F92EE;'>#IL-1#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9624, encryptionId=8d4596248e, topicName=IL-1)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f6cf9946833, createdName=jjjiang0202, createdTime=Sat Apr 29 09:58:00 CST 2017, time=2017-04-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1540492, encodeId=394f154049261, content=<a href='/topic/show?id=fbbce2786cc' target=_blank style='color:#2F92EE;'>#眼病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72786, encryptionId=fbbce2786cc, topicName=眼病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b85c13256921, createdName=pps20023, createdTime=Sat Apr 29 09:58:00 CST 2017, time=2017-04-29, status=1, ipAttribution=)]
    2017-04-29 fzwish20000
  5. [GetPortalCommentsPageByObjectIdResponse(id=1896030, encodeId=5dcd189603060, content=<a href='/topic/show?id=4a391158248' target=_blank style='color:#2F92EE;'>#MET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11582, encryptionId=4a391158248, topicName=MET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18fc139, createdName=一闲, createdTime=Thu Feb 22 04:58:00 CST 2018, time=2018-02-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1887618, encodeId=2fa3188e61817, content=<a href='/topic/show?id=d56611584ec' target=_blank style='color:#2F92EE;'>#Meta#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11584, encryptionId=d56611584ec, topicName=Meta)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d8f4110, createdName=guojianrong, createdTime=Mon May 15 13:58:00 CST 2017, time=2017-05-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2030725, encodeId=83a02030e2530, content=<a href='/topic/show?id=71353e8964f' target=_blank style='color:#2F92EE;'>#发生发展#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37896, encryptionId=71353e8964f, topicName=发生发展)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=346311, createdName=wgsun, createdTime=Tue Jan 30 19:58:00 CST 2018, time=2018-01-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1374409, encodeId=1e7113e440987, content=<a href='/topic/show?id=1727963861' target=_blank style='color:#2F92EE;'>#IL-17#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9638, encryptionId=1727963861, topicName=IL-17)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bcaa382, createdName=fzwish20000, createdTime=Sat Apr 29 09:58:00 CST 2017, time=2017-04-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1482900, encodeId=a69f1482900ed, content=<a href='/topic/show?id=2443963952' target=_blank style='color:#2F92EE;'>#IL-17A#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=134, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9639, encryptionId=2443963952, topicName=IL-17A)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0ae57859469, createdName=12498bf3m27暂无昵称, createdTime=Sat Apr 29 09:58:00 CST 2017, time=2017-04-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1508182, encodeId=6ffb15081829f, content=<a href='/topic/show?id=8d4596248e' target=_blank style='color:#2F92EE;'>#IL-1#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9624, encryptionId=8d4596248e, topicName=IL-1)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f6cf9946833, createdName=jjjiang0202, createdTime=Sat Apr 29 09:58:00 CST 2017, time=2017-04-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1540492, encodeId=394f154049261, content=<a href='/topic/show?id=fbbce2786cc' target=_blank style='color:#2F92EE;'>#眼病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72786, encryptionId=fbbce2786cc, topicName=眼病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b85c13256921, createdName=pps20023, createdTime=Sat Apr 29 09:58:00 CST 2017, time=2017-04-29, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=1896030, encodeId=5dcd189603060, content=<a href='/topic/show?id=4a391158248' target=_blank style='color:#2F92EE;'>#MET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11582, encryptionId=4a391158248, topicName=MET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18fc139, createdName=一闲, createdTime=Thu Feb 22 04:58:00 CST 2018, time=2018-02-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1887618, encodeId=2fa3188e61817, content=<a href='/topic/show?id=d56611584ec' target=_blank style='color:#2F92EE;'>#Meta#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11584, encryptionId=d56611584ec, topicName=Meta)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d8f4110, createdName=guojianrong, createdTime=Mon May 15 13:58:00 CST 2017, time=2017-05-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2030725, encodeId=83a02030e2530, content=<a href='/topic/show?id=71353e8964f' target=_blank style='color:#2F92EE;'>#发生发展#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37896, encryptionId=71353e8964f, topicName=发生发展)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=346311, createdName=wgsun, createdTime=Tue Jan 30 19:58:00 CST 2018, time=2018-01-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1374409, encodeId=1e7113e440987, content=<a href='/topic/show?id=1727963861' target=_blank style='color:#2F92EE;'>#IL-17#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9638, encryptionId=1727963861, topicName=IL-17)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bcaa382, createdName=fzwish20000, createdTime=Sat Apr 29 09:58:00 CST 2017, time=2017-04-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1482900, encodeId=a69f1482900ed, content=<a href='/topic/show?id=2443963952' target=_blank style='color:#2F92EE;'>#IL-17A#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=134, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9639, encryptionId=2443963952, topicName=IL-17A)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0ae57859469, createdName=12498bf3m27暂无昵称, createdTime=Sat Apr 29 09:58:00 CST 2017, time=2017-04-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1508182, encodeId=6ffb15081829f, content=<a href='/topic/show?id=8d4596248e' target=_blank style='color:#2F92EE;'>#IL-1#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9624, encryptionId=8d4596248e, topicName=IL-1)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f6cf9946833, createdName=jjjiang0202, createdTime=Sat Apr 29 09:58:00 CST 2017, time=2017-04-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1540492, encodeId=394f154049261, content=<a href='/topic/show?id=fbbce2786cc' target=_blank style='color:#2F92EE;'>#眼病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72786, encryptionId=fbbce2786cc, topicName=眼病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b85c13256921, createdName=pps20023, createdTime=Sat Apr 29 09:58:00 CST 2017, time=2017-04-29, status=1, ipAttribution=)]
    2017-04-29 jjjiang0202
  7. [GetPortalCommentsPageByObjectIdResponse(id=1896030, encodeId=5dcd189603060, content=<a href='/topic/show?id=4a391158248' target=_blank style='color:#2F92EE;'>#MET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11582, encryptionId=4a391158248, topicName=MET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18fc139, createdName=一闲, createdTime=Thu Feb 22 04:58:00 CST 2018, time=2018-02-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1887618, encodeId=2fa3188e61817, content=<a href='/topic/show?id=d56611584ec' target=_blank style='color:#2F92EE;'>#Meta#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11584, encryptionId=d56611584ec, topicName=Meta)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d8f4110, createdName=guojianrong, createdTime=Mon May 15 13:58:00 CST 2017, time=2017-05-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2030725, encodeId=83a02030e2530, content=<a href='/topic/show?id=71353e8964f' target=_blank style='color:#2F92EE;'>#发生发展#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37896, encryptionId=71353e8964f, topicName=发生发展)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=346311, createdName=wgsun, createdTime=Tue Jan 30 19:58:00 CST 2018, time=2018-01-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1374409, encodeId=1e7113e440987, content=<a href='/topic/show?id=1727963861' target=_blank style='color:#2F92EE;'>#IL-17#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9638, encryptionId=1727963861, topicName=IL-17)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bcaa382, createdName=fzwish20000, createdTime=Sat Apr 29 09:58:00 CST 2017, time=2017-04-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1482900, encodeId=a69f1482900ed, content=<a href='/topic/show?id=2443963952' target=_blank style='color:#2F92EE;'>#IL-17A#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=134, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9639, encryptionId=2443963952, topicName=IL-17A)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0ae57859469, createdName=12498bf3m27暂无昵称, createdTime=Sat Apr 29 09:58:00 CST 2017, time=2017-04-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1508182, encodeId=6ffb15081829f, content=<a href='/topic/show?id=8d4596248e' target=_blank style='color:#2F92EE;'>#IL-1#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9624, encryptionId=8d4596248e, topicName=IL-1)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f6cf9946833, createdName=jjjiang0202, createdTime=Sat Apr 29 09:58:00 CST 2017, time=2017-04-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1540492, encodeId=394f154049261, content=<a href='/topic/show?id=fbbce2786cc' target=_blank style='color:#2F92EE;'>#眼病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72786, encryptionId=fbbce2786cc, topicName=眼病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b85c13256921, createdName=pps20023, createdTime=Sat Apr 29 09:58:00 CST 2017, time=2017-04-29, status=1, ipAttribution=)]
    2017-04-29 pps20023

相关资讯

Molecular Psychiatry:实验小分子显示出预防冰毒复发的潜力

斯克里普斯研究所(TSRI)的新研究表明,甲基苯丙胺用户很难戒烟 - 即使康复后,其88%的患者复发,因为它是利用大脑的自然学习过程。

女性困扰,你真的懂吗?月经紊乱 查查甲状腺

女性困扰,你真的懂吗?月经紊乱 查查甲状腺

甲状腺癌:预防和治疗

甲状腺癌如何治疗,需要取出甲状腺吗?当使用碘治疗的时候,又是什么原理呢?治疗甲状腺癌通常需要取出全部或者部分甲状腺,当甲状腺癌发展到晚期时,推荐手术后使用碘放射治疗,防止手术中没有清除干净的癌细胞转移。对于非常小的乳头状甲状腺癌 (直径小于 1 厘米, 完全局限于甲状腺超声检查),可以不做手术,只需要定期观察,需要每年使用高清晰的超声波做甲状腺检查,这种小的甲状腺癌一般没有侵略性,尤其是对

甲状腺长有结节应如何处理?

甲状腺结节在中年以上人群并不少见。如果你发现甲状腺有结节性肿大,应该去医院检查超声和甲状腺功能(T3、T4和TSH),排除甲状腺功能亢进或减退。如果发现功能异常就要及时治疗。如果甲状腺功能正常,则主要是考虑结节是良性还是恶性的问题,因为恶性结节须考虑手术治疗,而良性结节则可以随访。要做甲状腺彩超和甲状腺核素扫描以了解甲状腺的形态与功能变化,协助确定甲状腺结节的的性质。必要时应穿刺活检确定结节性质。

甲状腺结节,傻傻分不清楚?一文弄懂!

如今,甲状腺结节的检出率越来越高,由于缺乏足够的了解,往往会给患者带来很大的心理压力。有些患者错误地把甲状腺结节完全等同于甲状腺癌,并为此而惶惶不安。

你为啥是“单身汪”?可能是甲状腺在搞鬼

马上就要到情人节了,各位单身汪想好怎么过了吗?宅在家里打一整晚游戏?约上好基友去酒吧彻夜狂欢?还是逛街被情侣秀恩爱残忍虐狗?其实,你成为一只单身汪,也许,另有隐情……

Baidu
map
Baidu
map
Baidu
map